Manoj Arra

Manoj Arra

Auto-generated profile, based on publicly available information

Manoj Arra

Department of Emergency Medicine, Washington University School of Medicine, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MAManoj Arra
Manoj Arra
GSGaurav Swarnkar
Gaurav Swarnkar
KKKe Ke
Ke Ke
JOJesse E. Otero
Jesse E. Otero
JYJun Ying
Jun Ying
Yousef Abu-AmerYousef Abu-Amer
Yousef Abu-Amer
The contribution of inflammation to the chronic joint disease osteoarthritis (OA) is unclear, and this lack of clarity is detrimental to efforts to identify therapeutic targets. Here we show that chondrocytes under inflammatory conditions undergo a metabolic shift that is regulated by NF-κB activation, leading to reprogramming of cell metabolism towards glycolysis and lactate dehydrogenase A (LDHA). Inflammation and metabolism can reciprocally modulate each other to regulate cartilage degradation. LDHA binds to NADH and promotes reactive oxygen species (ROS) to induce catabolic changes through stabilization of IκB-ζ, a critical pro-inflammatory mediator in chondrocytes. IκB-ζ is regulated bi-modally at the stages of transcription and protein degradation. Overall, this work highlights the function of NF-κB activity in the OA joint as well as a ROS promoting function for LDHA and identifies LDHA as a potential therapeutic target for OA treatment.

22 April 2023 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
MAM. Arra
M. Arra
Yousef Abu-AmerYousef Abu-Amer
Yousef Abu-Amer

6 June 2025 in The Journal of Emergency Medicine
Verified
Journal Article
Open access
MAManoj Arra
Manoj Arra
SMSasha Mozelewski-Hill
Sasha Mozelewski-Hill
TKTaylor Kaser
Taylor Kaser
RARachel Ancona
Rachel Ancona
PAPhilip Asaro
Philip Asaro
CHChristopher Holthaus
Christopher Holthaus
Sepsis is a high morbidity and mortality disease that is highly prevalent in emergency departments (EDs). Lactate is often utilized as a biomarker for sepsis, though its performance among subgroups such as obese patients is not well characterized. Given existing data on differences in lactate metabolism at baseline between obese and nonobese patients, this may be clinically relevant in sepsis identification and prognostication. We sought to compare differences in initial lactate measurements and lactate utility in predicting 30-day mortality between obese and nonobese body mass index (BMI) patients with vasopressor-dependent and non-vasopressor-dependent sepsis. We performed a retrospective cohort study of obese and nonobese patients presenting to an adult hospital ED with sepsis with organ dysfunction. Patients were separated into vasopressor-dependent or non-vasopressor-dependent groups. The primary outcomes were differences in initial lactate and utility of initial lactate in predicting 30-day all-cause mortality by employing receiver operator characteristic curves. Obese patients had lower initial lactate (2.2 mmol/L) compared with nonobese patients (2.4 mmol/L) in the non-vasopressor-dependent cohort. Lactate performed poorly-to-moderately well as a biomarker for 30-day mortality between obese and nonobese patients with sepsis, with no differences between BMI groups. Initial lactate levels are lower in obese patients compared with nonobese patients, but are unlikely to be clinically significant. We found no difference in lactate's utility as a biomarker for prediction of 30-day all-cause mortality between obese and nonobese patients. Lactate overall maintains some utility as a predictor of sepsis mortality, though factors that contribute to lactate levels remain unclear.